Share This Page
Drug Price Trends for NDC 00904-7067
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-7067
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CINACALCET HCL 30 MG TABLET | 00904-7067-04 | 0.30748 | EACH | 2024-12-18 |
| CINACALCET HCL 30 MG TABLET | 00904-7067-04 | 0.25418 | EACH | 2024-11-20 |
| CINACALCET HCL 30 MG TABLET | 00904-7067-04 | 0.39422 | EACH | 2024-10-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-7067
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
00904-7067 Market Analysis and Financial Projection
Market Analysis and Price Projections for Drug NDC: 00904-7067
Introduction
The pharmaceutical industry is a complex and dynamic market, influenced by various factors including regulatory changes, technological advancements, and competitive pressures. This article will focus on the market analysis and price projections for a specific drug identified by its National Drug Code (NDC) 00904-7067, although the specific drug name is not provided in the sources. We will explore general trends and factors that could impact the pricing and market dynamics of such a drug.
Understanding the NDC System
The National Drug Code (NDC) is a unique identifier assigned to each drug product by the FDA. It helps in tracking and managing drug products, including their pricing and market performance[5].
Market Trends in the Pharmaceutical Industry
The pharmaceutical industry is undergoing significant transformations driven by digital innovation, scientific advancements, and changing regulatory landscapes.
Digital Transformation and Innovation
In 2025, the life sciences industry is expected to see significant growth driven by digital transformation and innovation. Technologies like gen AI and increased data usage are anticipated to boost operational efficiencies and drive breakthrough innovations[3].
Pricing and Access
Pricing and access to drugs remain a major concern for the industry. Nearly half of the C-suite executives surveyed expect pricing and access issues to significantly impact their strategies in 2025. This highlights the need for companies to navigate external pressures on pricing and reimbursement effectively[3].
Competition from Generics and Biosimilars
Competition from generic drugs and biosimilars is another key trend. The patent cliff, with over $300 billion in sales at risk through 2030 due to expiring patents, is likely to drive interest in mergers and acquisitions. This competition can significantly impact the pricing and market share of branded drugs[3].
Price Trends in the Pharmaceutical Market
General Price Increases
The median price increase for brand-name drugs was 13.4% in 2022, which can serve as a benchmark for future price adjustments. This trend indicates that drug prices are generally on the rise, although specific drugs may vary based on market conditions and competition[2].
Impact of Patent Expiration
The expiration of patents on high-revenue products can lead to a significant decrease in sales for branded drugs. For example, in the NSCLC market, the patent expiration of drugs like Tarceva and Alimta has led to a decline in their sales, with generic versions capturing a substantial portion of the market[4].
Market Analysis for High-Expenditure Drugs
Medicare Market Share
Medicare plays a significant role in the market for high-expenditure drugs. For instance, Medicare represented at least half of the market for 22 of the 84 high-expenditure Part B drugs paid on the basis of Average Sales Price (ASP). This indicates that government programs can influence the pricing and market dynamics of these drugs[1].
NSCLC Market Example
In the Non-Small Cell Lung Cancer (NSCLC) market, premium-priced immune checkpoint inhibitor immunotherapies are driving growth. Drugs like Keytruda, Opdivo, and Tecentriq are expected to achieve blockbuster status by 2025, with sales projected to reach $17.5 billion. However, the patent expiration of other blockbuster drugs in this market will limit overall growth[4].
Price Projections
Given the lack of specific data on the drug with NDC 00904-7067, we can infer general price projection trends from the broader pharmaceutical market.
Impact of Competition
If the drug faces competition from generics or biosimilars, its price is likely to decrease. For example, the sales of generic pemetrexed are expected to reach $266 million by 2025, significantly impacting the sales of the branded version, Alimta[4].
Regulatory and Market Pressures
Pricing and access issues, as well as regulatory pressures, can also influence price projections. Companies may need to adjust their pricing strategies to maintain market share and comply with regulatory requirements[3].
Key Factors Influencing Price Projections
Patent Status
The patent status of the drug is crucial. If the patent is nearing expiration, the drug's price is likely to decrease as generic or biosimilar versions enter the market[3].
Market Competition
The level of competition in the market, including the presence of generic or biosimilar alternatives, will significantly impact the price of the drug[4].
Regulatory Environment
Changes in regulatory policies and reimbursement rates can also affect the pricing of drugs. For instance, Medicare's market share and pricing policies can influence the overall market dynamics[1].
Technological Advancements
Advances in technology, such as personalized medicine and the use of gen AI, can lead to more efficient production and potentially lower costs, although these may not always translate to lower prices for consumers[3].
Conclusion
The market analysis and price projections for a drug like the one identified by NDC 00904-7067 depend on several factors, including patent status, market competition, regulatory environment, and technological advancements. Here are some key takeaways:
- Pricing Trends: Drug prices are generally increasing, but specific trends can vary based on competition and regulatory changes.
- Competition: Generic and biosimilar competition can significantly reduce the price of branded drugs.
- Regulatory Impact: Medicare and other government programs can influence the pricing and market dynamics of high-expenditure drugs.
- Technological Advancements: Innovations in technology can improve efficiency but may not always lead to lower consumer prices.
Key Takeaways
- The pharmaceutical industry is driven by digital transformation, innovation, and changing regulatory landscapes.
- Pricing and access issues are significant concerns for the industry.
- Competition from generics and biosimilars can impact the pricing and market share of branded drugs.
- Patent expiration can lead to a decline in sales for branded drugs.
- Regulatory policies and government programs like Medicare can influence drug pricing.
FAQs
Q: What is the National Drug Code (NDC) and its significance? A: The NDC is a unique identifier assigned to each drug product by the FDA, helping in tracking and managing drug products, including their pricing and market performance[5].
Q: How does the patent cliff impact the pharmaceutical industry? A: The patent cliff, with over $300 billion in sales at risk through 2030 due to expiring patents, drives interest in mergers and acquisitions and significantly impacts the pricing and market share of branded drugs[3].
Q: What role does Medicare play in the market for high-expenditure drugs? A: Medicare represents a significant portion of the market for high-expenditure Part B drugs, influencing their pricing and market dynamics[1].
Q: How do technological advancements affect drug pricing? A: Technological advancements can improve production efficiency but may not always translate to lower prices for consumers. Instead, they often lead to more precise and effective treatments[3].
Q: What are the key factors influencing price projections for pharmaceutical drugs? A: Key factors include patent status, market competition, regulatory environment, and technological advancements.
Sources
- GAO Report: Medicare Represented at Least Half of the Market for 22 of the 84 High-Expenditure Part B Drugs Paid on the Basis of ASP[1].
- DrugPatentWatch: Latest drug prices and trends for NDC 00378-2245[2].
- Deloitte Insights: 2025 life sciences outlook[3].
- GlobalData: NSCLC Market - Global Drug Forecast & Market Analysis to 2025[4].
- FDA: National Drug Code Directory[5].
More… ↓
